{"name":"Arrys Therapeutics","slug":"arrys-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNdlcyRzc0UWU5ZHpXLUdsd1BFcFpKTkRuTl9xQkNoQVozR3ZTVkszMU1OdWJqb0ptR05TNHJfbFZaVFBxUlkyWkM5Sm96S1psbXNoVzlyeXRUM2FRMG53TGhVRHlna1B6c2x2UU93QzVySFA3UWJnX3pJYkRWNWRDeUI3UjVXZGdRbVRiV01RcmNrLURjVTYyWEp3dlpDUFBTaGh4aTR4dGdDbUQ0czhFNHhadnRleXRXOEdSRFBkOA?oc=5","date":"2024-06-04","type":"pipeline","source":"Healio","summary":"Durvalumab extends survival in limited-stage small-cell lung cancer - Healio","headline":"Durvalumab extends survival in limited-stage small-cell lung cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE1UX0U4MzF6eGh2NURIUUFIcUlxYU9UQ3l2RzcyNWdudDRhMXAxNi1GanlXV0FwMy1fMUZ0UU5wdWJCUXRJNjdIcDRUbUNhS0Rnb1Nrd3hzRFplM2JxakE3X3NybHhycWh3a1VBZHkzRzc5UQ?oc=5","date":"2022-02-15","type":"pipeline","source":"MedPage Today","summary":"Long-Term Survival Benefit in NSCLC With Another Anti-PD-1/L1 Drug - MedPage Today","headline":"Long-Term Survival Benefit in NSCLC With Another Anti-PD-1/L1 Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOaUVuQ2pHVlBoN2dIX04wZGxueGk3NTNRTWJsQUhwcVZfQ05YMHlCNjJMcE9uVEVBS0FsdXhPVnFzNkhleHA1QzZ6Z2JlWDc5blFnZ3M2bXU3eFBqNWFfeUVybnNIMGFveGZLSlcyZ1NvbUtnN1Jid2xtSjA5QlFLSFFURzF1RWtIT2JRbUhzVlRWSGZJc09mSWhLSHc3WE12ZXk1ZlRCYw?oc=5","date":"2019-07-01","type":"deal","source":"fiercepharma.com","summary":"Array CEO Squarer's set to reap $210M in Pfizer buyout—and his COO and CMO won't do badly, either - fiercepharma.com","headline":"Array CEO Squarer's set to reap $210M in Pfizer buyout—and his COO and CMO won't do badly, either","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}